Amphastar Pharmaceuticals Inc
0.0 %
-31.11 %
Yet to be announced
Company Overview
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company that focuses on developing, manufacturing, and marketing generic and proprietary injectable, inhalation, and intranasal products. The company develops, manufactures, and markets generic and proprietary pharmaceutical products including injectable, inhalation, and intranasal products.
The company's product portfolio includes various critical care and emergency medical treatments used in hospitals and urgent care centers. Their business model is centered around pharmaceutical manufacturing and sales, with no significant involvement in non-halal activities.
Revenue Sources
Based on SEC filings and company reports, Amphastar's revenue is primarily derived from the development, manufacture, and sale of pharmaceutical products. Their product portfolio consists of medical treatments that are permissible under Islamic law. The company does not derive significant revenue from any haram sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $191.21m | $140.86m | - | $6.7m | 0.00% | 4.75% |
| June 30, 2024 | $182.39m | $135.79m | - | $8.61m | 0.00% | 6.34% |
| March 31, 2024 | $171.84m | $132.44m | - | $8.61m | 0.00% | 6.50% |
| Dec. 31, 2023 | $178.1m | $133.58m | - | $9.46m | 0.00% | 7.08% |
Analysis of the company's financial statements over the past four quarters shows that interest expenses relative to total expenses have remained below the 5% threshold consistently. The company maintains a manageable level of interest-bearing debt that does not indicate excessive leverage or dependence on interest-based financing.
Operational Ethics
Based on available information from SEC filings and company disclosures, Amphastar Pharmaceuticals does not maintain significant operations or partnerships with entities involved in human rights violations. The company's primary manufacturing facilities are located in the United States and France, with no significant presence in regions of concern.
Login to join the discussion